Dr Reddy’s semaglutide delay: key updates for 2026

Supply delay triggers investor focus

Dr Reddy's Laboratories said it is delaying commercial supplies of semaglutide after identifying an issue linked to the active pharmaceutical ingredient (API) used in the drug. The update, reported by Reuters on July 9, came as the company also launched its semaglutide injection, Obeda, in India for diabetes. The company said certain batches of semaglutide were found to be out of specification. It said it is investigating the root cause and taking measures to ensure product quality. Dr Reddy’s added that there is no impact on patient safety. It also said there is no impact on the product’s existing global regulatory filings. The company did not provide a timeline for when supplies would normalise, and did not disclose further details.

What Dr Reddy’s said about the quality issue

In its statement, Dr Reddy’s linked the supply delay to the API used in semaglutide. The company’s disclosure focused on product quality controls rather than demand constraints. By stating that batches were out of specification, the company signalled a manufacturing or process-related deviation that needs investigation. Dr Reddy’s said it is working on root cause identification, which typically involves checking raw material attributes, process parameters, and analytical results across batches. The company also said it is taking measures to ensure product quality, indicating corrective and preventive actions are underway. Importantly, it clarified there is no impact on patient safety. It also stated that existing global regulatory filings are unaffected, suggesting the issue is being handled within established regulatory and quality frameworks.

Obeda launch in India: product format and dosing

Alongside the supply update, Dr Reddy’s has launched its semaglutide injection, Obeda, in India to treat diabetes. A company leadership team that spoke during the launch said Obeda is available in 2 mg and 4 mg strengths. The product comes in a pre-filled, disposable format designed for subcutaneous administration. It is intended for once-a-week dosing. The company described the delivery mechanism as a user-friendly pen device. These details position Obeda within the standard patient-use formats common for injectable GLP-1 therapies.

Competitive backdrop after patent expiry in India

The supply delay comes at a time of heightened competition in India’s semaglutide market. Sun Pharmaceutical, Dr Reddy's Laboratories, Zydus Life Sciences, and Glenmark Pharmaceuticals rolled out generic versions of semaglutide on March 21 after the expiration of the patent on the active ingredient in India. Semaglutide is the key ingredient in Novo Nordisk’s Ozempic (for diabetes) and Wegovy (for weight loss). With patent expiry, multiple Indian companies have moved to build presence in a category that has drawn significant consumer and investor attention. The competitive environment increases the importance of execution in manufacturing, quality, and sustained supply.

Regulatory status: Ozempic generic approved, Wegovy generic awaited

Dr Reddy’s has said it received approval from India’s drug regulator to manufacture and sell a generic version of Novo Nordisk’s blockbuster diabetes drug Ozempic. The company has also said it is awaiting a regulator’s nod for a generic version of Wegovy, the weight-loss drug. In another update referenced in the material provided, a Dr Reddy’s executive said the company has sufficient production capacity to meet demand and plans to collaborate with local partners in India for the semaglutide launch. These regulatory milestones matter because they define which indications the company can market for in India and how quickly it can scale distribution within compliant product labels.

International filings: Health Canada timelines and complexity

Outside India, the materials referenced an ongoing regulatory process in Canada. Dr Reddy’s is awaiting further guidance from Health Canada after filing a response in November to a notice of non-compliance stating the drug does not meet regulatory requirements. The regulator has 180 days to respond, and Dr Reddy’s expected a response by May, according to comments attributed to the company’s CEO. Separately, the materials also note that Health Canada introduced additional requirements due to the complexity of making semaglutide, and that Novo Nordisk uses living cells to produce the drug while most generics companies rely on a chemical process. These points underline why semaglutide filings can involve extended review cycles and additional data requests.

Legal context: export permission and India sales restriction

The materials also described a court development involving Dr Reddy’s and Novo Nordisk. In a Dec. 2 decision, the Delhi High Court dismissed Novo Nordisk’s application to block production of semaglutide, allowing Dr Reddy’s to manufacture and export to countries where patent protection does not apply. However, the court barred Dr Reddy’s from domestic sales until March 2026, when Novo Nordisk’s secondary patent expires, as cited in the provided text. Court documents referenced in the material said Dr Reddy’s began producing the drug in April, and the company confirmed it would not sell in India until the patent expiry timeline. The court also ordered the company to keep a record of the quantity and value of products manufactured and sold.

Pricing signals and volume plans highlighted by analysts and management

Analyst commentary cited in the materials suggested generic semaglutide could be priced as low as $10 (₹3,600) in 2026, less than half the current price of Ozempic in India, according to Nomura analyst Saion Mukherjee. Separately, the materials said Novo Nordisk entered the Indian market with Wegovy in June, pricing the drug between ₹17,000 and ₹25,000 per month. Dr Reddy’s CEO Erez Israeli was quoted in the provided material as saying the company is preparing to manufacture 12 million semaglutide injection pens in the first year of sales and that it will be making the active ingredient in the drug. These numbers are central to how investors frame market sizing, affordability, and supply readiness, even as the company manages the current out-of-specification batch issue.

Key facts table

Market impact and why the update matters

The immediate market reaction was negative, with Reuters reporting that the update sent Dr Reddy’s shares down, though no percentage move was provided. For investors, the key issue is not only near-term shipment timing but also what the quality deviation implies for repeatability at scale. Semaglutide is a high-profile product category, and a supply delay tied to an API-linked specification issue can raise questions about manufacturing controls, vendor qualification, and release testing cadence. At the same time, Dr Reddy’s statement that patient safety is not impacted and that global filings remain unaffected helps limit the scope of concern to commercial supply timing rather than regulatory risk. The company’s lack of a timeline means markets may stay cautious until there is clarity on how quickly batches return to specification and when regular supplies resume.

Conclusion

Dr Reddy’s has delayed commercial semaglutide supplies after identifying out-of-specification batches linked to the API, while stating there is no impact on patient safety or existing global regulatory filings. The company has launched Obeda in India, with 2 mg and 4 mg once-weekly pen formats, and is progressing with approvals for generic Ozempic while awaiting a decision for generic Wegovy. The next major updates investors are likely to track are the company’s findings from the root-cause investigation, any guidance on the duration of the supply disruption, and regulatory timelines in key markets referenced in the company’s prior disclosures.